APA (7th ed.) Citation

Bian, Y., Meng, J., Ma, S., Li, G., Wang, Y., Li, S., . . . Miao, L. (2022). Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers. British journal of clinical pharmacology, 88(7), 3307-3320. https://doi.org/10.1111/bcp.15256

Chicago Style (17th ed.) Citation

Bian, Yicong, et al. "Metabolite Profiles and Mass Balance of Fuzuloparib, a Novel Poly (ADP‐ribose) Polymerase Inhibitor, in Subjects with Advanced Solid Cancers." British Journal of Clinical Pharmacology 88, no. 7 (2022): 3307-3320. https://doi.org/10.1111/bcp.15256.

MLA (9th ed.) Citation

Bian, Yicong, et al. "Metabolite Profiles and Mass Balance of Fuzuloparib, a Novel Poly (ADP‐ribose) Polymerase Inhibitor, in Subjects with Advanced Solid Cancers." British Journal of Clinical Pharmacology, vol. 88, no. 7, 2022, pp. 3307-3320, https://doi.org/10.1111/bcp.15256.